

Inhalable Biologics Market Analysis 2025 – Insights for Long-Term Investment & Planning

*The Business Research Company's
Inhalable Biologics Global Market Report
2025 – Market Size, Trends, And Global
Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, June 17, 2025

/EINPresswire.com/ -- What Is The
Growth Trajectory Of The [Inhalable
Biologics Market?](#)



The Business
Research Company

The Business Research Company

The [inhalable biologics market size](#) has grown rapidly in recent years. It will grow from \$2.79 billion in 2024 to \$3.25 billion in 2025 at a compound annual growth rate CAGR of 16.4%. The growth in the historic period can be attributed to increasing respiratory disease prevalence

worldwide, growing demand for non-invasive delivery, rising awareness of biologics' benefits, and increasing biopharma research and investment.

“

The Business Research
Company's Latest Report
Explores Market Driver,
Trends, Regional Insights -
Market Sizing & Forecasts
Through 2034.

”

*The Business Research
Company*

Where Is The Inhalable Biologics Market Headed?

The market size is projected to see exponential growth in the next few years, with estimates showing it will grow to \$5.90 billion in 2029 at a CAGR of 16.0%. The growth during the forecast period can be attributed to rising global aging population rates, increasing healthcare infrastructure in emerging markets, growing regulatory biologics therapy support, and a rise in infectious respiratory disease cases.

Significant trends emerging in the forecast period include advancements in drug delivery systems, integration of smart inhaler technology, technology innovations in aerosol science, developments in biologic drug formulations, and advancements in nanoparticle-based carriers.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp>

What's Fueling The Inhalable Biologics Market Growth?

An increase in respiratory conditions is expected to propel the growth of the inhalable biologics

market. Respiratory conditions encompass diseases and disorders impacting the lungs and other parts of the respiratory system, including the airways, nasal passages, and lungs. The prevalence of these respiratory conditions is attributed to increasing air pollution, which exacerbates conditions like asthma, chronic obstructive pulmonary disease COPD, and lung cancer by exposing individuals to harmful particulate matter and other pollutants. Inhalable biologics have shown to be beneficial for these respiratory conditions as they enable targeted treatment delivery directly to the lungs, reducing inflammation and improving lung function—with fewer systemic side effects.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report>

Who are the key players in the Inhalable Biologics market?

The industry is driven by major companies such as Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Inmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., and MannKind Corporation.

What Are The Emerging Trends In The Inhalable Biologics Market?

In terms of trends and advancements, companies are focusing on the development of innovative solutions such as inhaled insulin to enhance patient compliance and ensure rapid glycemic control. For instance, in 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval for Afrezza, the world's fastest inhaled insulin, offering a revolutionary, needle-free option for adults with type 1 and type 2 diabetes.

How Is The Inhalable Biologics Market Segmented?

The inhalable biologics market is segmented as follows:

- 1 By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
- 2 By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
- 3 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- 4 By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:

- 1 Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
- 2 Vaccines: Influenza Vaccines, Other Respiratory Vaccines

3 Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies

4 RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics

5 Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

What Are The Regional Insights Into The Inhalable Biologics Market?

North America held the lion's share in the inhalable biologics market in 2024. However, Asia-Pacific is expected to be the fastest-growing region in the near future. The regions covered in this report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Inhalation Anesthesia Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report>

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report>

Inhalation Sedatives Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/inhalation-sedative-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/822909129>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.